Abacus Pharma Ltd Pharmaceutical Import Profile — Uganda (DGFT 2022–2026)

Name: Abacus Pharma Ltd Pharmaceutical Import Records from India — 3 Products, $1.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Abacus Pharma Ltd — Pharmaceutical Importer Profile (2026) | 3 Products, $1.9M Trade | TransData Nexus

Abacus Pharma Ltd

Pharmaceutical Importer · Uganda · Antibiotics Focus · $1.9M Total Trade · DGFT Verified

Abacus Pharma Ltd is a pharmaceutical importer based in Uganda with a total trade value of $1.9M across 3 products in 3 therapeutic categories. Based on 39 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Abacus Pharma Ltd sources from 1 verified Indian supplier, with Cipla Limited accounting for 100.0% of imports.

Abacus Pharma Ltd — Import Portfolio & Supplier Network

Abacus Pharma Ltd import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Abacus Pharma Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$702.5K	97	100.0%

Abacus Pharma Ltd sources from 1 verified Indian supplier across 38 distinct formulations. The sourcing is highly concentrated — Cipla Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Abacus Pharma Ltd Import?

Formulation	Value	Ships
Pylokit (lansoprazole CAPS 30MG+tinidazole tablets 500MG+clarithromycin tablets 250MG kit)	$150.0K	3
Pylokit (lansoprazole CAPS 30MG+tinidazole tablets 500MG+clarithromycin tablets 250MG kit) [10584(packs	$54.4K	3
Pylokit (lansoprazole CAPS 30MG+tinidazole tablets 500MG+clarithromycin tablets 250MG kit) [52653(packs	$50.0K	1
Pylokit (lansoprazole CAPS 30MG+tinidazole tablets 500MG+clarithromycin tablets 250MG kit) [52920(packs	$50.0K	1
Pylokit (lansoprazole CAPS 30MG+tinidazole tablets 500MG+clarithromycin tablets 250MG kit)[50022(packs	$50.0K	1
Esomac-40 mups (esomeprazole 40MG) [6960(packs	$36.8K	1
Cipladon 1000MG tablet (paracetamol 1000 MG) [16650(packs	$31.0K	1
Fucol 200 capsule (fluconazole 200MG) [13101(packs	$30.3K	3
Fucol 200 capsule (fluconazole 200MG) [12997(packs	$30.0K	3
I-pill TAB (levonorgestrel 1.5MG)	$24.4K	4
Pylokit (lansoprazole CAPS 30MG+tinidazole tablets 500MG+clarithromycin tablets 250MG kit) [4872(packs	$23.5K	1
Esomac-20 mups (esomeprazole 20MG) [5880(packs	$22.3K	1
Esomac-40 mups (esomeprazole 40MG) [4080(packs	$21.4K	1
Cipladon 500MG tablet (paracetamol 500MG) [10640(packs	$19.8K	1
Esomac-20 mups (esomeprazole 20MG) [5160(packs	$19.7K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Clarithromycin	Antibiotics	$650.0K	13	0.7%	13
2	Lansoprazole	Gastrointestinal	$650.0K	13	0.2%	14
3	Tinidazole	Advanced Antibiotics	$650.0K	13	3.5%	2

Abacus Pharma Ltd imports 3 pharmaceutical products across 3 categories into Uganda totaling $1.9M.

Abacus Pharma Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Abacus Pharma Ltd, established in 1995 and headquartered in Kampala, Uganda, is a leading distributor and manufacturer of pharmaceutical products in East Africa. The company operates across Uganda, Kenya, Tanzania, Rwanda, and Burundi, with a significant presence in the region. Abacus Pharma Ltd offers a diverse portfolio, including cardiovascular drugs, respiratory medications, anti-infective agents, and over-the-counter products.

In 2009, Abacus Pharma Ltd expanded its operations by establishing Abacus Parenteral Drugs Limited (APDL) in Mukono, Uganda. This 11,000 square meter facility is now the largest parenteral manufacturing plant in East Africa, supplying a substantial portion of the region's demand for parenteral drugs.

2Distribution Network

Abacus Pharma Ltd maintains an extensive distribution network with seven warehouses and 60 wholesale outlets across East Africa. This infrastructure enables the company to effectively serve a wide customer base, including hospitals, pharmacies, and healthcare providers.

3Industry Role

Abacus Pharma Ltd plays a pivotal role in Uganda's pharmaceutical supply chain as a primary wholesaler and distributor. The company's operations encompass the importation, distribution, and manufacturing of a broad range of pharmaceutical products, ensuring the availability of essential medicines throughout the region.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Abacus Pharma Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Abacus Pharma Ltd's sourcing strategy exhibits a high degree of concentration, with a total import value of $1.9 million USD from India across 39 shipments, all supplied by a single Indian supplier, CIPLA LIMITED. This single-source dependency may pose risks related to supply chain disruptions, pricing fluctuations, and potential challenges in negotiating favorable terms. The absence of alternative suppliers could impact the company's ability to mitigate these risks effectively.

2Supply Chain Resilience

The resilience of Abacus Pharma Ltd's Indian supply chain is currently limited due to its reliance on a single supplier, CIPLA LIMITED. This dependency may expose the company to potential disruptions in case of supply chain issues, regulatory changes, or geopolitical events affecting India. Diversifying the supplier base and establishing relationships with multiple manufacturers could enhance supply chain resilience and reduce vulnerability to such risks.

3Strategic Implications

The current sourcing pattern of Abacus Pharma Ltd, characterized by a concentrated supplier base, may impact its competitive position by limiting flexibility in pricing, product availability, and responsiveness to market changes. For Indian exporters, this presents an opportunity to become alternative suppliers by offering competitive pricing, reliable delivery schedules, and high-quality products to meet Abacus Pharma Ltd's needs.

Importing Pharmaceuticals into Uganda — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Uganda

1Regulatory Authority & Framework

In Uganda, the National Drug Authority (NDA) is the primary regulatory body overseeing the importation and distribution of pharmaceutical products. The National Drug Policy and Authority Act (Cap 206) and the Regulations on Importation and Exportation of Drugs (S.I 34, 2014) govern the pharmaceutical sector. These regulations stipulate that entities must possess a valid import license and a license to operate a pharmacy to import drugs into Uganda. (nda.or.ug)

2Import Licensing & GMP

To import pharmaceutical products into Uganda, companies must obtain an import license from the NDA, valid for one year within the calendar year of issuance. Additionally, the imported drugs must be accompanied by a Verification Certificate for each consignment, issued by the NDA prior to importation. The NDA recognizes Good Manufacturing Practice (GMP) certificates from reputable authorities, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S), ensuring that imported products meet international quality standards. (nda.or.ug)

3Quality & Labeling

Abacus Pharma Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Abacus Pharma Ltd's focus on importing products in the therapeutic areas of antibiotics, gastrointestinal treatments, and advanced antibiotics aligns with the prevalent health challenges in Uganda and the broader East African region. The market demand for these products is driven by the high incidence of infectious diseases, gastrointestinal disorders, and the need for advanced antibiotic therapies to combat resistant strains. By concentrating on these categories, Abacus Pharma Ltd aims to address critical healthcare needs and strengthen its market position.

2Sourcing Profile

Abacus Pharma Ltd's sourcing strategy emphasizes the procurement of generic drug formulations, primarily from India, to provide affordable and effective treatment options. The company's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, ensures that products are ready for immediate distribution and use. India's established pharmaceutical manufacturing capabilities and competitive pricing make it a strategic partner in Abacus Pharma Ltd's overall procurement strategy.

3Market Positioning

Seller's Guide — How to Become a Supplier to Abacus Pharma Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter the Ugandan market by offering competitive pricing, reliable delivery schedules, and high-quality products. Abacus Pharma Ltd's current sourcing pattern, characterized by a concentrated supplier base, presents an opportunity for alternative suppliers to establish relationships and diversify the company's supply chain. Identifying and addressing any gaps in Abacus Pharma Ltd's current sourcing strategy can lead to mutually beneficial partnerships and enhanced market presence.

2Requirements & Qualifications

Indian exporters seeking to supply Abacus Pharma Ltd and the Ugandan market must ensure that their products comply with international quality standards, such as WHO GMP and PIC/S certifications. Additionally, they must obtain the necessary import licenses and Verification Certificates from the NDA for each consignment. Adhering to labeling requirements, including the use of English and local languages, and meeting serialization mandates are essential to ensure market acceptance and regulatory compliance.

3How to Approach

Frequently Asked Questions — Abacus Pharma Ltd

What products does Abacus Pharma Ltd import from India?

Abacus Pharma Ltd imports 3 pharmaceutical products across 3 categories. Top imports: Clarithromycin ($650.0K), Lansoprazole ($650.0K), Tinidazole ($650.0K).

Who supplies pharmaceuticals to Abacus Pharma Ltd from India?

Abacus Pharma Ltd sources from 1 verified Indian suppliers. The primary supplier is Cipla Limited (100.0% of imports, $702.5K).

What is Abacus Pharma Ltd's total pharmaceutical import value?

Abacus Pharma Ltd's total pharmaceutical import value from India is $1.9M, based on 39 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Abacus Pharma Ltd focus on?

Abacus Pharma Ltd imports across 3 categories. The largest: Antibiotics (33.3%), Gastrointestinal (33.3%), Advanced Antibiotics (33.3%).

Get Full Abacus Pharma Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.